Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
Lucia Del Mastro(Ospedale Policlinico San Martino), Francesco Cognetti(Apple (Israel)), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Fabio Puglisi(University of Udine), Claudia Bighin(Azienda Ospedaliera S.Maria), Paolo Bruzzi(Alleanza Contro il Cancro), Giovanna Cavazzini(University of Padua), Filippo Montemurro(Roche (Switzerland)), Andrea Ardizzoni(Azienda Ospedaliero-Universitaria Careggi), Teresa Gamucci, C. Boni(Ospedale Santa Maria), Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giancarlo Bisagni, Valeria Forestieri(University of Naples Federico II), Sandro Barni, Mario Giuliano(Regione Campania), Anna Turletti(Ospedale Martini), Sabino De Placido, Giuseppe Colantuoni(Azienda Ospedaliera S.Giuseppe Moscati), Paola Papaldo(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Adriano Gravina(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Enrichetta Valle(Regione Puglia), Antonio Durando(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)
Cited by 201
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830